Tenofovir continues to suppress hepatitis B virus for eight years
Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients
Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients
Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection
Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4
Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis
